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Summary B-cell chronic lymphocytic leukaemia (CLL) cannot be cured by conventional therapy. To improve the prognosis of patients with
CLL, we have designed a sequential treatment strategy that comprises intensive chemotherapy for mobilization of peripheral blood progenitor
cells (PBPCs) and induction of minimal disease, followed by high-dose radiochemotherapy with stem cell reinfusion and post-transplant
molecular monitoring by polymerase chain reaction (PCR) amplification of the complementary determining region IlIl (CDRIII) gene. In a
prospective study, we have evaluated this protocol in 18 patients with CLL, also including early stages of the disease. The median age was
49 (29-61) years; Binet stages were A, six; B, nine; and C, three. Adverse prognostic factors [high lymphocyte count and/or diffuse bone
marrow (BM) infiltration] were present in 16 out of 18 patients. All patients showed a clone-specific molecular marker as demonstrated by
PCR amplification of CDRIII rearrangements. For stem cell mobilization and reduction of tumour load, one to two cycles of Dexa-BEAM
chemotherapy were administered, resulting in minimal disease (circulating lymphoma cells <1 x 1091-1; BM infiltration <20%; lymphomas <2
cm) in 16 out of 18 patients, including four patients who already had minimal disease before Dexa-BEAM. Stem cell harvesting was
successful in 14 patients. All grafts [three BM, 11 peripheral blood (PB)] were purged from leukaemic cells using immunomagnetic methods.
Thirteen patients having achieved minimal disease were reinfused with purged autologous stem cells (ASC) after preparation with total body
irradiation and cyclophosphamide. Engraftment was delayed in patients receiving BM (n = 3) but prompt [neutrophils >0.5 x 109 1- after 10
(9-13) days, platelets >20 x 1091- after 11 (9-214) days] in patients restored with PBPCs (n = 10). Procedure-related deaths did not occur.
Although the results of CDRIII PCR suggest persistence or recurrence of the leukaemic clone in at least three cases, to date only one patient
has relapsed, whereas all others survive without clinical evidence of disease with a maximum follow-up of 48 months. We conclude that
sequential high-dose therapy using Dexa-BEAM and autologous stem cell transplantation is a safe and highly effective treatment for patients
with CLL. However, a longer follow-up is needed to assess whether definite cures can be achieved using this strategy.
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B-cell chronic lymphocytic leukaemia (CLL) is not curable with
conventional chemotherapy. Although the natural course of the
disease is often indolent, a considerable reduction in survival time
must be expected ifadverse prognostic factors, such as high leuco-
cyte count, diffuse bone marrow infiltration, short lymphocyte
doubling time, unfavourable cytogenetics or advanced stage, are
present (Rozman and Montserrat, 1995). Thus, in particular for
younger patients, new treatment modalities are required that have
the potential to provide long-term remissions or to completely
eradicate the disease. Preliminary reports suggest that myeloabla-
tive radiochemotherapy with subsequent autologous bone marrow
transplantation (BMT) may have curative potential in CLL
(Rabinowe et al, 1993; Khouri et al, 1994; Provan et al, 1996).
Wider use of autologous BMT for treatment of CLL has been
hindered by a number of concerns. First, autografts from patients
with CLL are frequently contaminated with significant amounts of
leukaemic cells, necessitating ex vivo tumour cell depletion
('purging') of the graft to reduce potential sources of relapse. In
addition, CLL is a disease of the elderly, rendering myeloablative
radiochemotherapy with prolonged cytopenias, as usually seen
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after transplantation of purged marrow, particularly difficult. The
use of peripheral blood progenitor cells (PBPCs) instead of BM
can shorten the duration of post-transplant aplasia dramatically,
especially if ex vivo purged autografts are compared (Schmitz et
al, 1996; Dregeret al, 1995a) and should thus be particularly bene-
ficial in patients with CLL.
Second, relapses have been observed after BMT, especially in
those patients who had a large tumour load before high-dose therapy
(Khouri et al, 1994), suggesting that - similar to other haematolog-
ical neoplasias - achievement of a state of minimal disease before
autografting is an important prerequisite for a favourable outcome
(Bastion et al, 1995; Haas et al, 1996). Therefore it might be advis-
able (1) to consider high-dose therapy early during the course ofthe
disease and (2) to reduce the leukaemic burden by cytoreductive
chemotherapy before transplant.
Finally, in the patients remaining in clinical remission during the
early post-transplant phase, complete eradication ofCLL is impos-
sible to assess using clinical criteria or conventional haematolog-
ical methods, implying that sensitive immunological or molecular
markers are needed for adequate monitoring of minimal residual
disease. In patients with CLL, molecular-genetic monitoring can be
performed using the immunoglobulin heavy-chain (IgH) gene as a
disease-specific marker. During B-cell maturation, three different
germ-line gene segment families (variable, V; diversity, D;joining,
J) of the IgH gene undergo specific rearrangements. One result of
this process is the third complementary determining region
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Table 1 Patient characteristics and response to Dexa-BEAM
UPN Age/sex Pretreatment Binet stage Status at mobilization Response
to D-BEAM
Maximum At mobilization BM infiltration (%) PB B cells (x109 1-1)
035 29/M CHOPx4 B A 5 6 CR
074 30/M CHOEPx4 B B 40 1 CR
083 39/M CHOPx4 B A 5 1 CR
096 57/M CHOPx6 B B 60 4 MRD
099 51/F Chlorambucil x13 B B 60 2 MRD
119 47/F CHOP x8, FAMP x5 C B 50 1 MRD
132 46/M Chlorambucil x3, C C 20 12 PR
COP x2, VIM x7
134 49/M CHOPx3 B B 5 2 MRD
176 57/M No A A 10 7 CR
187 51/F CHOP x2, mantle field irradiation B B 20 2 Refractory
206 48/M CHOPx5 B B 90 2 CR
216 61/M CHOP x8, FAMP x5 B A 0 0.5 CR
230 48/M Chlorambucil x19, B B 40 44 MRD
CHOP x6
236 54/M No B B NA 1 MRD
238 49/F COP x2 A A 50 36 MRD
253 39/M Chlorambucil x13, C C 20 18 MRD
COP x3, FAMP x3
256 51/M No C C 50 14 MRD
271 47/F No A A 5 17 MRD
CHOP, cyclophosphamide, doxorubicine, vincristin, prednisolone; CHOEP, cyclophosphamide, doxorubicine, vincristin, etoposide, prednisolone; COP,
cyclophosphamide, vincristin, prednisolone; FAMP, fludarabine monophosphate; VIM, etoposide, ifosfamide, methotrexate; NA, not available.
(CDRIII), which encodes for one of three CDR regions of the
heavy chains. By insertion of non-coding N-regions between the
rearranged gene segments a highly variable sequence (VH-N-DH-
N-JH) is generated, which is unique for each individual B-cell
clone (Schroeder and Dighiero, 1994; Linke et al, 1995). Using
consensus primers annealing for conserved sequences within the V
and J regions, the CDRIII rearrangement can be amplified by poly-
merase chain reaction (PCR). Depending on the number of non-
malignant B cells in the sample, the sensitivity of CDRIII PCR
followed by separation of the amplified DNA fragments by poly-
acrylamide gel electrophoresis (PAGE) is about one clonal cell in
103-104 normal cells (Suttorp et al, 1996).
Taken together, autografting in patients with CLL should be facil-
itated by using PBPCs instead of marrow grafts, should have a
stronger curative potential if performed early during the course of
the disease or after induction of remission by conventional
chemotherapy, and requires sensitive monitoring of residual disease
post transplant. Based on these considerations, we have designed a
sequential treatment strategy that comprises the Dexa-BEAM
regimen (dexamethasone, BCNU, etoposide, ara-C, melphalan) for
PBPC mobilization and induction of minimal disease, high-dose
radiochemotherapy followed by stem cell reinfusion, andpost-trans-
plant molecular monitoring by CDRIII PCR. In a prospective study,
we have evaluated this protocol in patients with poor prognosis
CLL, including those with early-stage disease. Ourpreliminary data
indicate that this sequential approach is feasible and safe, and can
result in long-term clinical and molecular remissions.
PATIENTS AND METHODS
Patients
Patients with a diagnosis ofB-cell chronic lymphocytic leukaemia
and lymphoplasmocytoid immunocytoma, according to the Kiel
classification (Stansfield et al, 1988), or B CLL and 'B CLL
variant', respectively, according to the REAL classification
(Harris et al, 1994), were eligible if they were between 18 and 65
years old, had an adequate performance status and were capable of
understanding and giving informed consent. Between March 1993
and May 1996, eighteen patients (five female; 13 male) fulfilling
these criteria were included. The median age was 49 (29-61)
years. Four patients presented with untreated disease, whereas 14
had previously received one to three chemotherapy regimens
(Table 1). Binet stages at the time ofenrolment in the study were A
in six patients, B in nine patients and C in three patients, whereas
the maximum stages during the course of the disease were A in
three patients, B in 11 patients and C in four patients. Adverse
prognostic factors (diffuse BM infiltration pattern or lymphocyte
count greater than 50 x 109 1-1; Rozman and Montserrat, 1995)
were present in 16 out of 18 patients. Two patients with early CLL
(P176 and P271) were referred for autografting even though they
did not fulfill these poor-risk criteria. They requested treatment
even after thorough information about the risks and the uncertain
benefits of the procedures. Patients were treated according to a
protocol approved by the institutional review board.
Assessment of response and treatment protocol
Complete response (CR) was defined as the complete absence of
specific lesions as assessed by physical examination, computer-
ized tomographic (CT) scans ofthe chest, abdomen and pelvis, the
presence ofa normal BM biopsy and less than 1 x 109 1-1 B cells in
the peripheral blood. A partial remission (PR) was defined as a
reduction in measurable lesions by >50% without appearance of
new lesions for at least 8 weeks, and a reduction in BM infiltration
to <20% of the intertrabecular space. To fulfill the criteria of
'minimal disease' (MRD), a CR or a PR with less than 1 x 109 1-'
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Table 2 Results of purging
PB CD34+ (Isolex) PB B- (MaxSep) BM B- (MaxSep)
Patientsa 6 5 3
CD34 + cells in final product (x106 kg-') 2.9 (0.7-4) 4 (1-7.8) 0.4 (0.3-0.6)
CD19+ CD5+ cells in final product (x106 kg-1) 0 (0-0.006) 0 0
PCR status of final product Pos. 5, neg. 1 Pos 3, neg. 2 Pos 3, neg. 0
aPurging was not performed in four patients because of low CD34+ counts in the collection products.
B cells in the peripheral blood and with residual lymphoma masses
less than 2 cm in diameter was required. Refractory disease was
defined as a response less than PR.
After initial staging, eligible patients underwent one course of
Dexa-BEAM chemotherapy followed by PBPC harvesting.
Patients not in CR at time ofentry into the study were treated with
a second Dexa-BEAM cycle (which was used for stem cell collec-
tion in individual patients with high tumour load before the first
Dexa-BEAM), followed by clinical restaging. If a state of MRD
was achieved, patients proceeded to high-dose therapy. Restaging,
including physical examination, thoracoabdominal CT scan, BM
biopsy and PCR analysis of peripheral blood and BM samples,
was performed at 3, 6 and 12 months and then every 12 months
after autologous stem cell transplantation (ASCT).
Administration of chemotherapy and progenitor cell
collection
The Dexa-BEAM regimen included dexamethasone 3 x 8 mg days
(d) 1-10, BCNU 60 mg m- d 2, etoposide 75-250 mg m-' d 4-7,
cytarabine 100 mg m-2 q 12 h d 4-7 and melphalan 20 mg m-2 d 3
(Pfreundschuh et al, 1994). Patients received filgrastim (5-10 ,ug kg-'
s.c. daily; Amgen, Munich, Germany) from d 8 after the start of
Dexa-BEAM until the last day of PBPC collection. Leukapheresis
was performed as described previously (Dreger et al, 1993). A
median oftwo (one to four) leukapheresis procedures was performed
on consecutive days. Purging ofPBPCs and BM grafts, respectively,
was performed by immunomagnetic B-cell depletion using CD19,
CD20, CD23 and CD37 monoclonal antibodies with the MaxSep
System (Baxter Biotech Immunotherapy Division, Munich,
Germany) by immunomagnetic CD34+ selection with the Isolex 300
System (Baxter Immunotherapy Division, Irvine, USA).
High-dose chemotherapy and progenitor cell reinfusion
Myeloablative therapy consisted of fractionated total-body irradia-
tion (TBI) 6 x 2 Gy on 3 consecutive days followed by cyclo-
phosphamide 2 x 60 mg kg-'. Daily filgrastim (5-10 ,ug kg-') was
administered to all patients post transplant to accelerate neutrophil
recovery. Neutrophil recovery was defined as the first of3 consecu-
tive days with a neutrophil count >0.5 x 109 1-, platelet recovery
was defined as the first day with an unsupported platelet count
>20 x 109 1-'. Patients were discharged from hospital after the white
blood count had recovered (3 days above 1 x 1091-I) in the absence
of fever, parenteral nutrition or intravenous antibiotics. Supportive
care was performed as described elsewhere (Schmitz et al, 1996).
Immunophenotypical analysis
Immunophenotypical analysis was performed using flow cytometry.
Details of the staining procedure and enumeration of CD34+
progenitor cells and residual lymphoma cells have been described
elsewhere (Dreger et al, 1995b). In brief, cells were incubated with
FITC-, PE- and PerCP-conjugated antibody, respectively, fixed with
1% formaldehyde and acquired to a FACScan flow cytometer
(Becton Dickinson, Heidelberg, Germany). Multidimensional eval-
uations were performed with Facscan orCellquest Software (Becton
Dickinson). The antibodies used were: 8G12-PE, 8G12-FITC
(HPCA-2/CD34), Leu-M3-PE (CD33), HLe-l-FITC (CD45), Leu-
12-FITC, Leu-12-PerCP (CDl9), Leu-1-PE (CD5, all from Becton
Dickinson) and MHM6-FITC (CD23, Dako, Hamburg, Germany).
PCR
Analysis of CDRIII rearrangements was carried out by two-step
semi-nested PCR amplification using the oligonucleotide primers
FR3A (5'-ACACG GC[C/T][G/C)] GTATT ACTGT-3') for the
FR3IgH region, LJH (5'-TGAGG AGACG GTGAC C-3') for the
JH-external region and VLJH (5'-GTGAC CAGGG TNCCT
TGGCC CCAG-3') for the JH-intemal region as previously
described (Suttorp et al, 1996). Negative and positive controls
were included in each assay. CDRIII PCR amplification products
were separated on a non-denaturing polyacrylamide gel (Clean
Gel; Pharmacia, Freiburg, Germany). Bands were visualized by
silver staining. As determined by serial dilution experiments, PCR
allows detection of approximately one tumour cell in 103-104
normal cells.
RESULTS
Response to Dexa-BEAM
After one or two cycles of Dexa-BEAM, a complete or very good
partial remission (equal to MRD) was achieved in 16 of 18 patients
(88%), including four patients who already had MRD before
Dexa-BEAM. One patient was refractory and another patient
showed only a partial remission in terms of lymphoma size.
However, in all 18 patients peripheral blood B cells were reduced
below 1 x 1091-' and BM infiltration decreased to less than 20% of
intertrabecular space (Table 1). The overall response rate in the 14
patients not presenting with MRD before Dexa-BEAM was 93%.
Stem cell mobilization
PBPC mobilization was excellent in most patients. A median of
11 x 106 kg-} (0.2-54.1) CD34+ cells was harvested with two (two to
four) leukapheresis procedures. The individual maximum percentage
of CD34+ cells in the collection products was 3.2% (0.1-19.4%).
Two patients did not reach the target dose of 2 x 106, kg' CD34+
cells. CDl9+CD5+ B cells were detectable in all PBPC harvests
(median 2.4 x 106 kg', range 0.2-707), and a clonal CDRIII
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Figure 1 Molecular monitoring of autografted patients using CDRIII PCR
(PAGE). *, BM grafts; * PBPC grafts; A/A, peripheral blood samples; 0/0,
BM samples; open symbols, PCR polyclonal; closed symbols, PCR clonal; R,
clinical relapse
rearrangement could be amplified from apheresis samples in all
patients.
Immunomagnetic purging of PBPC collection products was
performed in 11 patients and reduced the number ofcontaminating
lymphoma cells below the threshold of detection by FACS in 9 of
11 grafts. However, PCR negativity was achieved in only three
cases (Table 2). In four patients the CD34+ cell counts appeared
too low or the B-cell counts too high to justify purging attempts.
The PBPC products of the first three patients were not purged
because the technology of ex vivo processing of PBPC was not
available at that time. These patients were autografted with B-cell-
depleted marrow with their PBPC grafts stored as backup.
High-dose therapy and haematopoietic reconstitution
Thirteen patients who had a successful stem cell graft collection and
fulfilled the criteria of MRD proceeded to high-dose therapy and
ASCT. Engraftment was delayed in the three patients receiving
purged BM (neutrophils >0.5 x 109 1-' after 20-31 days; platelets
>20 x 109 1-1 after 46-165 days) but prompt and durable in the
patients restored with PBPC [neutrophils >0.5 x 109 1-' after 10
(9-13) days, platelets >20 x 109 1-1 after 11 (9-214) days, platelet
count 3 months post transplant 149 (16-265) x 1091-']. Two patients
(P074 reconstituted with BM and P230 reconstituted with a PBPC
graft containing only I x 106 kg-' CD34+ cells) had delayed platelet
and red cell engraftment, requiring transfusion for more than 6
months post transplant. Procedure-related deaths did not occur.
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Figure 2 Progression-free survival after mobilization with Dexa-BEAM.-,
Autografted patients; - - -, patients who were not eligible for autografting
Outcome and molecular follow-up
All 13 autografted patients are alive with a median follow-up of 19
(12-48) months and were available for prospective molecular
monitoring using PCR amplification of CDRIII rearrangements.
Although clonality was frequently observed in the first 3 months
post transplant, with one exception (P238), peripheral blood and
marrow of all patients showed polyclonal results during longer
follow-up (Figure 1). However, in two patients (P035 and P083,
both autografted with purged BM), clonal bands reappeared 45
and 25 months post transplant respectively. In the latter patient
(P083), clonal cells with a CLL-like immunophenotype
(CD19+CD5+) became detectable in the peripheral blood by flow
cytometry at 37 months and were taken as evidence for clinical
relapse. All other patients are disease-free by stringent clinical
criteria.
Five patients were considered uneligible for autografting
because of insufficient response to Dexa-BEAM, poor stem cell
mobilization or heavy tumour cell contamination of the graft
(P096, P119, P132, P187, P253). P253 received an allogeneic
PBPC graft and died due to P. carinii pneumonia 13 months post
transplant while being in complete molecular remission. All others
experienced disease progression 1-26 months after mobilization
but are still alive under conventional therapy, except for P132 who
succumbed to progressive leukaemia 26 months after Dexa-
BEAM (Figure 2).
DISCUSSION
Although high-dose therapy followed by ASCT is widely used for
a variety of neoplastic diseases, including low-grade lymphoma,
the number of patients with CLL having been treated with this
modality is very limited. Apart from a few small-sized series
(Bastion et al, 1992; Itala et al, 1997; Michallet and Apperley,
1997), there have been only three studies that are comparable to
ours with regard to patient number and follow-up, one from the
Dana-Farber Cancer Institute, one from the MD Anderson Cancer
Center and one from the Nebraska Medical Center (Rabinowe et
al, 1993; Khouri et al, 1994; Gribben et al, 1995; Provan et al,
1996; Pavletic et al, 1997).
The restrained use of this potentially curative treatment for an
otherwise incurable disease might be explained by the disease-
specific difficulties that are present in CLL: most patients are rela-
tively old; the systemic tumour load is usually high when
autografting is considered; BM and peripheral blood are often
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heavily infiltrated by leukaemic cells; and the therapeutic benefit
of ASCT is difficult to evaluate because of the slow natural course
of the disease. Thus, as outlined above and discussed elsewhere
(Dreger and Schmitz, 1997), a high-dose approach for patients
with CLL must fulfill the following requirements: (1) it should be
safe and well tolerable; (2) it should involve effective strategies to
reduce the systemic tumour load and to obtain grafts depleted of
tumour cells; and (3) it should use sensitive methods to detect
residual or recurring disease post transplant. With the present
protocol, we have attempted to meet all of these requirements by
using PBPCs as the principal source of stem cells, by prefering
patients being in an early stage, by inducing a pre-transplant state
of minimal disease with intensive salvage chemotherapy, by
performing immunomagnetic purging ofthe grafts and by prospec-
tive molecular monitoring of minimal disease during follow-up.
Our data show that even after ex vivo purging, PBPCs dramati-
cally shorten the duration of cytopenia and, thus, should reduce
associated complications, such as mucositis, susceptibility to
infections and transfusion requirements. The time required to
achieve neutrophil and platelet recovery after PBPC transplanta-
tion was clearly below the minimum time to engraftment observed
in our three patients receiving BM as well as in the patients
communicated by the Dana-Farber and MD Anderson groups, who
were all reconstituted with marrow (Rabinowe et al, 1993; Khouri
et al, 1994). Durable engraftment was achieved in all patients, and
there was no treatment-related mortality. At the most recent
follow-up, 10 of 13 autografted patients had resumed working
activities, indicating that the risk of severe long-term morbidity
related to ASCT is limited. In addition, taking into account our
experience with this sequential high-dose regimen in more than 50
patients with low-grade lymphoma without any procedure-related
death, one can conclude that the mortality of Dexa-BEAM
followed by high-dose therapy and autologous PBPC transplanta-
tion is low, resembling that of conventional treatments, such as
fludarabine (Keating et al, 1993; Sorensen et al, 1997), but
contrasts with the experience of former series performed using
allogeneic or autologous BMT (Khouri et al, 1994; Gribben et al,
1995; Michallet et al, 1996).
In our hands, the Dexa-BEAM protocol is a safe and effective
regimen for the treatment ofB-CLL. In all patients including those
with considerable leukaemic cell load, Dexa-BEAM was able to
reduce BM infiltration to 20% or less and to decrease lymphocyte
numbers below I x 109 1-'; thus, a state of minimal disease could
be achieved in the vast majority of patients. Another advantage of
this regimen is its excellent stem cell mobilizing capacity (Dreger
et al, 1993). Furthermore, Dexa-BEAM has obviously an 'in-vivo
purging' effect because B cells were strongly reduced in the
majority of collection products (median ratio CD34 count-CD19
count 2.2: 1). This effect is particularly important if ex vivo
purging is considered and it appears to be more pronounced after
Dexa-BEAM than after regimens such as high-dose cyclophos-
phamide, which has been frequently used for stem cell mobiliza-
tion in patients with CLL (Itala et al, 1997; Michallet and
Apperley, 1997). For these reasons, Dexa-BEAM was also chosen
for PBPC mobilization in the patients presenting with minimal
disease, when being considered for autografting.
Five of 18 patients did not complete the protocol because of
inadequate stem cell mobilization (n = 3), poor response to Dexa-
BEAM (n = 1) or both (n = 1). It is noteworthy that mobilization
failures occurred in three of four stage C patients opposed to only
1 of 14 stage A or B patients.
Even if their clinical relevance is uncertain, the large amounts of
cells with leukaemic phenotype, which are frequently present in
unmanipulated autografts, are a potential source of relapse. In
contrast to the Dana-Farber patients, who received highly B-cell-
depleted autografts and had a low incidence of disease recurrence,
frequent relapses occurred in the MD Anderson and Nebraska
series after reinfusion of unpurged stem cells (Khouri et al, 1994;
Provan et al, 1996; Pavletic et al, 1997). Although these observa-
tions certainly provide no clear-cut evidence, ex vivo purging
appears to be essential in patients with CLL. In contrast to marrow
grafts, PBPC collection products have the advantage that their
engraftment potential is not or only slightly reduced by immuno-
logical purging (Brugger et al, 1994; Shpall et al, 1994; Dreger et
al, 1995a; Straka et al, 1995). During the course of this study, our
B-cell depletion procedures were steadily refined. Whereas the
technology of PBPC purging was not available for the first three
patients (who were therefore treated with purged marrow), positive
or negative stem cell selection from PBPC collection products
could be successfully applied to 11 of the 15 subsequent patients
and resulted in complete elimination of FACS-detectable tumour
cells in nine of them. Currently, we are using a combined posi-
tive/negative selection method that can deplete up to 6 logs ofCLL
cells from PBPC grafts (Paulus et al, 1997).
As far as clinical criteria are concerned, only one of the 13 auto-
grafted patients shows any evidence of relapse to date. However,
the follow-up is still very short for patients with CLL. Thus, we
performed prospective molecular monitoring post transplant using
consensus primer CDRIII PCR with polyacrylamide gel electro-
phoresis to assess the eradication of leukaemia at a molecular
level. During the first few months after autografting, most patients
showed clonal signals that disappeared during longer follow-up.
This phenomenon has also been observed by others (Provan et al,
1996) and might be explained by the persistence of leukaemic but
not clonogenic cells or by oligoclonal reconstitution of the B-cell
system post transplant (Mitus et al, 1989; Fischer et al, 1990).
There was only one patient (P238) who did not convert to PCR
negativity but is still in clinical remission 14 months after auto-
grafting. All other patients have exhibited polyclonal bands during
longer follow-up, although P035 and P083 showed weak clonal
signals at 45 and 25 months respectively. Dot blotting using
tumour-specific probes confirmed that these bands were of
leukaemic origin. P083 progressed to clinical relapse 12 months
later. In an additional patient (PO99), who remained polyclonal by
PAGE, leukaemic DNA could be identified with a tumour-specific
probe (data not shown), implying that there is at least a subgroup
of patients being resistent to complete leukaemia eradication by
this approach. This is in agreement with data reported by Provan et
al (1996) for autologous BMT and has prompted us to use addi-
tional criteria for selecting candidates for sequential high-dose
therapy to better identify those patients who have proliferating and
thus sensitive tumour cells while being at high risk for disease
progression. These criteria include adverse prognostic factors,
such as elevated levels of serum thymidine kinase and beta-2-
microglobulin or unfavourable cytogenetics (Hallek et al, 1996;
Dohner et al, 1995; Dohner et al, 1997). A German multicentre
trial is currently under way to study the approach presented here in
larger numbers of patients with early CLL associated with these
poor prognostic parameters.
Taken together, early sequential high-dose therapy using Dexa-
BEAM and autologous stem cell transplantation appears to be a
highly effective treatment for patients with CLL. However, the
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data are still preliminary, and larger patient numbers and a longer
follow-up are required to confirm that this approach can indeed
improve the prognosis ofpoor-risk CLL.
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